The increase in richness of the TCR repertoire in the periphery of anti-CTLA-4 treated patients, suggested to result from unleashed T-cell priming, could be expected to enhance immune control of the tumor through the generation of new T cell responses covering a broader range of neoantigens [63]. This evidence concerns the gene CTLA4 and neoplasm.